← Back to headlines
Merck & Co. Highlights TERN-701 Potential in $6.7B Terns Pharma Acquisition
Pharmaceutical giant Merck & Co. has announced its intention to acquire Terns Pharma for $6.7 billion, touting the 'best-in-class' potential of TERN-701 for Chronic Myeloid Leukemia (CML) as a key driver for the deal.
28 Mar, 20:55 — 28 Mar, 20:55
Sources
Showing 1 of 1 sources
